 |
PDBsum entry 4ql1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transcription/inhibitor
|
PDB id
|
|
|
|
4ql1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Transcription/inhibitor
|
|
|
Title:
|
|
Crystal structure of human wdr5 in complex with compound oicr-9429
|
|
Structure:
|
|
Wd repeat-containing protein 5. Chain: a, b. Synonym: bmp2-induced 3-kb gene protein. Engineered: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Gene: wdr5, big3. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
|
|
1.50Å
|
R-factor:
|
0.196
|
R-free:
|
0.227
|
|
|
Authors:
|
|
A.Dong,L.Dombrovski,J.R.Walker,M.Getlik,E.Kuznetsova,D.Smil, D.Barsyte,F.Li,G.Poda,G.Senisterra,R.Marcellus,R.Al-Awar,C.Bountra, C.H.Arrowsmith,A.M.Edwards,P.J.Brown,M.Schapira,M.Vedadi,H.Wu, Structural Genomics Consortium (Sgc)
|
|
Key ref:
|
|
F.Grebien
et al.
(2015).
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
Nat Chem Biol,
11,
571-578.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
10-Jun-14
|
Release date:
|
17-Dec-14
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
P61964
(WDR5_HUMAN) -
WD repeat-containing protein 5 from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
334 a.a.
304 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Nat Chem Biol
11:571-578
(2015)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
|
|
F.Grebien,
M.Vedadi,
M.Getlik,
R.Giambruno,
A.Grover,
R.Avellino,
A.Skucha,
S.Vittori,
E.Kuznetsova,
D.Smil,
D.Barsyte-Lovejoy,
F.Li,
G.Poda,
M.Schapira,
H.Wu,
A.Dong,
G.Senisterra,
A.Stukalov,
K.V.Huber,
A.Schönegger,
R.Marcellus,
M.Bilban,
C.Bock,
P.J.Brown,
J.Zuber,
K.L.Bennett,
R.Al-Awar,
R.Delwel,
C.Nerlov,
C.H.Arrowsmith,
G.Superti-Furga.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The CEBPA gene is mutated in 9% of patients with acute myeloid leukemia (AML).
Selective expression of a short (30-kDa) CCAAT-enhancer binding protein-α
(C/EBPα) translational isoform, termed p30, represents the most common type of
CEBPA mutation in AML. The molecular mechanisms underlying p30-mediated
transformation remain incompletely understood. We show that C/EBPα p30, but not
the normal p42 isoform, preferentially interacts with Wdr5, a key component of
SET/MLL (SET-domain/mixed-lineage leukemia) histone-methyltransferase complexes.
Accordingly, p30-bound genomic regions were enriched for MLL-dependent H3K4me3
marks. The p30-dependent increase in self-renewal and inhibition of myeloid
differentiation required Wdr5, as downregulation of the latter inhibited
proliferation and restored differentiation in p30-dependent AML models.
OICR-9429 is a new small-molecule antagonist of the Wdr5-MLL interaction. This
compound selectively inhibited proliferation and induced differentiation in
p30-expressing human AML cells. Our data reveal the mechanism of p30-dependent
transformation and establish the essential p30 cofactor Wdr5 as a therapeutic
target in CEBPA-mutant AML.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Links
